Skip to content
Screener

Alumis Inc. ALMS Business Segments — Research And Development Expense

Similar metrics at other companies

Napco Security Technologies logo
NSSCSingle Reportable — Research And Development Expense
$400K+22.0%
Capricor Therapeutics logo
CAPRSingle Reportable — Research And Development Expense
$27.38M+44.7%
Plug Power logo
PLUGSingle Reportable — Research And Development Expense
$12.11M-30.2%
Dogwood Therapeutics logo
DWTXSingle Reportable — Research And Development Expense
$2.67M+9.6%
908 Devices logo
MASSSingle Reportable — Research And Development Expense
$3.47M-9.3%
Merit Medical Systems logo
MMSISingle Reportable — Research And Development Expense
$22.61M+0.6%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Internal costs
Personnel-related costs26,06517,659
Facilities and overhead costs5,3735,192
Total research and development expense81,54096,622
General and administrative expenses18,61022,295
Total operating expenses100,150118,917
Loss from operations(98,409)(101,528)
Total other income (expense), net5,3562,565

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s business segments — research and development expense?
Alumis Inc. (ALMS) reported business segments — research and development expense of $81.54M in Q1 2026.
How has Alumis Inc.'s business segments — research and development expense changed year-over-year?
Alumis Inc.'s business segments — research and development expense decreased by 15.6% year-over-year, from $96.62M to $81.54M.
What is the long-term trend for Alumis Inc.'s business segments — research and development expense?
Over 2 years (2023 to 2025), Alumis Inc.'s business segments — research and development expense has grown at a 67.4% compound annual growth rate (CAGR), from $137.68M to $386M.
What does business segments — research and development expense mean?
The aggregate of all costs incurred in the research and development of new products, including personnel, clinical trials, and overhead. This is a primary indicator of the company's commitment to innovation and the advancement of its clinical pipeline.

Ask your AI about Alumis Inc.'s business segments — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude